These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25863582)

  • 1. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
    Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
    J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
    Li L; Pan Z
    Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
    Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.
    Elia EG; Städler N; Ciani O; Taylor RS; Bujkiewicz S
    Cancer Epidemiol; 2020 Feb; 64():101665. PubMed ID: 31911395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
    Sidhu R; Rong A; Dahlberg S
    Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free Survival as a Surrogate End-point in Advanced Colorectal Cancer Treated with Antiangiogenic Therapies.
    Montagnani F; DI Leonardo G; Pino MS; Martella F; Perboni S; Ribecco A; Fioretto L
    Anticancer Res; 2016 Aug; 36(8):4259-65. PubMed ID: 27466541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-free survival is a surrogate for survival in advanced colorectal cancer.
    Buyse M; Burzykowski T; Carroll K; Michiels S; Sargent DJ; Miller LL; Elfring GL; Pignon JP; Piedbois P
    J Clin Oncol; 2007 Nov; 25(33):5218-24. PubMed ID: 18024867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
    Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
    Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of surrogate endpoints for predicting real-world survival across five cancer types.
    Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
    Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
    Chibaudel B; Bonnetain F; Shi Q; Buyse M; Tournigand C; Sargent DJ; Allegra CJ; Goldberg RM; de Gramont A
    J Clin Oncol; 2011 Nov; 29(31):4199-204. PubMed ID: 21969501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
    Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
    Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
    Michiels S; Saad ED; Buyse M
    Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
    Gyawali B; Hey SP; Kesselheim AS
    JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).
    Shi Q; Schmitz N; Ou FS; Dixon JG; Cunningham D; Pfreundschuh M; Seymour JF; Jaeger U; Habermann TM; Haioun C; Tilly H; Ghesquieres H; Merli F; Ziepert M; Herbrecht R; Flament J; Fu T; Coiffier B; Flowers CR
    J Clin Oncol; 2018 Sep; 36(25):2593-2602. PubMed ID: 29975624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials.
    Shitara K; Ikeda J; Yokota T; Takahari D; Ura T; Muro K; Matsuo K
    Invest New Drugs; 2012 Jun; 30(3):1224-31. PubMed ID: 21350803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.